HeartBeam Inc (BEAT)
2.32
-0.07
(-2.93%)
USD |
NASDAQ |
Dec 26, 15:52
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 61.86M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 13.81% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | -- |
| Price to Book Value | 12.89 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | -- |
Profile
| HeartBeam Inc is a medical technology company primarily focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company’s ability to develop higher-resolution ECG solutions is achieved through the development of the Company’s proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products. |
| URL | https://www.heartbeam.com |
| Investor Relations URL | https://ir.heartbeam.com/ |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Health Care Equipment & Supplies |
| Equity Style | Small Cap/Value |
| Next Earnings Release | Mar. 20, 2025 (est.) |
| Last Earnings Release | Nov. 07, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| HeartBeam Inc is a medical technology company primarily focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company’s ability to develop higher-resolution ECG solutions is achieved through the development of the Company’s proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products. |
| URL | https://www.heartbeam.com |
| Investor Relations URL | https://ir.heartbeam.com/ |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Health Care Equipment & Supplies |
| Equity Style | Small Cap/Value |
| Next Earnings Release | Mar. 20, 2025 (est.) |
| Last Earnings Release | Nov. 07, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |